Sibutramine Treatment in Obesity: Predictors of Weight Loss Including Rorschach Personality Data-Reference-Cited by-同舟云学术

Sibutramine Treatment in Obesity: Predictors of Weight Loss Including Rorschach Personality Data

Published:2003-11 Issue:11 Volume:11 Page:1391-1399
ISSN:1071-7323
Container-title:Obesity Research
language:en
Short-container-title:

Author:

Elfhag Kristina,Rössner Stephan,Carlsson Anna Maria,Barkeling Britta

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Endocrinology,Endocrinology, Diabetes and Metabolism,Food Science,Medicine (miscellaneous)

Reference53 articles.

1. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine;Heal;Int J Obes,1998

2. Effect of sibutramine on weight maintenance after weight loss: a randomised trial;James;Lancet,2000

3. Sibutramine: a review of its contribution to the management of obesity;McNeely;Drugs,1998

4. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity: results from the European multi-centre STORM trial;Hansen;Int J Obes,2001

5. Sibutramine produces dose-related weight loss;Bray;Obes Res,1999

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the management of obesity: a review of current evidence and emerging therapies;Expert Review of Endocrinology & Metabolism;2024-04-29

2. Therapeutic advances in obesity management: an overview of the therapeutic interventions;Frontiers in Endocrinology;2024-04-23

3. Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders;Experimental and Clinical Gastroenterology;2024-03-26

4. Platform introducing individually tailored variability in nerve stimulations and dietary regimen to prevent weight regain following weight loss in patients with obesity;Obesity Research & Clinical Practice;2021-03

5. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome;Therapeutic Advances in Endocrinology and Metabolism;2020-01